Integra Lifesciences Holdings (IART) Liabilities and Shareholders Equity (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Liabilities and Shareholders Equity data on file, last reported at $3.6 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 11.72% year-over-year to $3.6 billion; the trailing twelve-month figure through Mar 2026 stood at $14.5 billion (down 10.7% YoY), and the FY2025 full-year result was $3.6 billion, down 10.78% from the prior year.
• Liabilities and Shareholders Equity slipped to $3.6 billion in Q1 2026, from $3.6 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $4.1 billion in Q1 2024 to a low of $3.6 billion in Q1 2026.
• A 5-year average of $3.8 billion and a median of $3.8 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity gained 8.97% in 2024 and dropped 11.72% in 2026, its largest moves.
• Tracing IART's Liabilities and Shareholders Equity over 5 years: stood at $3.9 billion in 2022, then dropped by 2.77% to $3.8 billion in 2023, then advanced by 6.75% to $4.0 billion in 2024, then retreated by 10.78% to $3.6 billion in 2025, then dropped by 0.67% to $3.6 billion in 2026.
• Business Quant data shows IART's Liabilities and Shareholders Equity at $3.6 billion in Q1 2026, $3.6 billion in Q4 2025, and $3.6 billion in Q3 2025.